ICON Public (NASDAQ:ICLR) Downgraded to “Neutral” Rating by The Goldman Sachs Group

ICON Public (NASDAQ:ICLR) was downgraded by The Goldman Sachs Group from a “buy” rating to a “neutral” rating in a research note issued on Friday, MarketBeat.com reports. They presently have a $200.00 price target on the medical research company’s stock, down from their prior price target of $250.00. The Goldman Sachs Group’s target price would suggest a potential upside of 8.18% from the company’s current price.

A number of other brokerages have also issued reports on ICLR. Robert W. Baird decreased their target price on shares of ICON Public from $221.00 to $203.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Royal Bank of Canada restated an “outperform” rating and set a $263.00 target price on shares of ICON Public in a research report on Wednesday, January 15th. Truist Financial decreased their target price on shares of ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Barclays decreased their target price on shares of ICON Public from $275.00 to $240.00 and set an “overweight” rating on the stock in a research report on Friday, February 21st. Finally, JPMorgan Chase & Co. decreased their target price on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $272.50.

ICON Public Trading Up 0.5 %

Shares of ICON Public stock opened at $184.87 on Friday. ICON Public has a 12-month low of $174.93 and a 12-month high of $347.72. The company has a current ratio of 1.26, a quick ratio of 1.34 and a debt-to-equity ratio of 0.36. The stock has a market cap of $14.93 billion, a PE ratio of 19.40, a price-to-earnings-growth ratio of 1.86 and a beta of 1.21. The company has a 50-day moving average of $192.76 and a two-hundred day moving average of $226.31.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.41 by $0.01. The business had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.04 billion. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. On average, research analysts anticipate that ICON Public will post 13.38 EPS for the current fiscal year.

Hedge Funds Weigh In On ICON Public

A number of hedge funds have recently made changes to their positions in the stock. Sierra Ocean LLC purchased a new position in shares of ICON Public in the 4th quarter valued at $29,000. Park Place Capital Corp raised its stake in shares of ICON Public by 281.4% in the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 166 shares during the period. Private Trust Co. NA raised its stake in shares of ICON Public by 48.8% in the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock valued at $52,000 after acquiring an additional 82 shares during the period. GAMMA Investing LLC raised its stake in shares of ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 169 shares during the period. Finally, Horizon Investments LLC raised its stake in shares of ICON Public by 534.0% in the 4th quarter. Horizon Investments LLC now owns 653 shares of the medical research company’s stock valued at $137,000 after acquiring an additional 550 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.